Appendix A: Training and Construction of Algorithm-Based Biological Aging Measures

Klemera-Doubal Biological Age

Following the approach described by Levine (Levine, 2013), we calculated NHANES participants' biological ages using the Klemera-Doubal equation (Klemera and Doubal, 2006). The equation takes information from *m* number of regression lines of *m* biomarkers regressed on chronological age:

$$BA_{EC} = \frac{\sum_{j=1}^{m} (x_j - q_j) \frac{k_j}{s_j^2} + \frac{CA}{s_{BA}^2}}{\sum_{j=1}^{m} \left(\frac{k_j}{s_j}\right)^2 + \frac{1}{s_{BA}^2}}, \text{ where } x \text{ is the value of biomarker } j \text{ measured for an individual in the 1999-}$$

2002 NHANES. To ensure independence of the Klemera-Doubal Biological Age algorithm from the 1999-2002 NHANES database, we estimated all algorithm parameters from a reference dataset composed of the NHANES III and 2003-2014 Continuous NHANES panels. For each biomarker j, the parameters q, k, and s were estimated from a regression of the biomarker on chronological age in the reference dataset. q, k, and s, are the regression intercept, slope, and root mean squared error, respectively. s_{BA} is a scaling factor equal to the square root of the variance in chronological age explained by the biomarker panel in the reference database. CA is chronological age. The biomarkers used to compose the algorithm were: serum albumin, alkaline phosphatase, blood urea nitrogen, creatinine, C-reactive protein, glycated hemoglobin, total cholesterol, uric acid, white blood cell count, lymphocyte percent, mean corpuscular volume, and systolic blood pressure. Biomarkers with skewed distributions were log-transformed for analysis (alkaline phosphatase, creatinine, C-reactive protein, uric acid, and white blood cell count). Following Levine (Levine, 2013), regressions of chronological age on biomarker values included all NHANES participants aged 30-75 years and not pregnant at the time of assessment. The year of NHANES data collection was included in regressions as a panel of dummy variables to account for year-to-year variation in laboratory methods. The model intercept was set to the 2003-2004 NHANES panel. Models were estimated separately for men and women. Summary statistics

describing biomarker distributions in the training sample are reported in **Appendix Table A.1**. For each biomarker, model R-squared (R), root-mean-squared-error (S), intercept (Q), and age-coefficient (K) were saved and used to compute the S²BA parameter. Parameters are reported in **Appendix Table A.2**. These parameters were used to form the Klemera-Doubal Biological Age algorithm in our study.

We implemented the Klemera-Doubal Biological Age Algorithm using biomarker data for NHANES 1999-2000 and 2001-2002 participants aged 20-84. To account for any differences in laboratory procedures between 1999-2000 and 2001-2002 NHANES panels used for analysis and the training sample, we re-centered analysis-sample biomarker values around the sex-specific means for the 2003-2004 NHANES panel, which formed the intercept in regressions used to develop the Klemera-Doubal Biological Age Algorithm. We then computed Klemera-Doubal-Method (KDM) Biological Ages according to the equation above. Pregnant women were excluded, as were participants with data on fewer than ten of the twelve biomarkers. Klemera-Doubal Biological Age was pro-rated to account for missing biomarkers; missing parameters were imputed as the average of the observed parameters.

Appendix Table A.1: Biomarker descriptive statistics for the reference population used to train the Klemera-Doubal Biological Age Algorithm. The reference population consisted of men and women aged 30-75 years participating in NHANES III and continuous NHANES panels collected during 2003-2016 (N=38,028, 49% male). Pregnant women were excluded.

			Women			Men	
	Units ® f®						
Biomarker	Measure	M	SD	N	M	SD	N
Albumin	g/dL	4.13	(0.33)	77771 8,456	4.29	(0.33)	77771 7,506
Alkaline Phosphatase	log ∄ U/L	4.28	(0.33)	77771 8,446	4.28	(0.30)	77771 7,503
Blood Turea Initrogen	mg/dL	12.74	(4.70)	27771 8,373	14.17	(4.81)	77771 7,443
Creatinine	log⊡mg/dL	0.60	(0.11)	77771 8,389	0.71	(0.11)	77771 7,450
C-Reactive r rotein	log@mg/dL	-1.24	(1.10)	mm12,714	-1.50	(1.03)	mm12,071
Glycated⊞emoglobin	%	5.70	(0.97)	77771 8,636	5.75	(1.01)	77771 7,624
Uric ® Acid	log⊡mg/dL	1.74	(0.22)	77771 8,448	1.94	(0.19)	77771 7,513
Lymphocyte⊞ercent	%	32.19	(8.43)	77771 8,712	30.82	(8.53)	77771 7,683
White Blood Cell Count	log ™ I	2.07	(0.25)	77771 8,746	2.07	(0.25)	77771 7,708
Mean © orpuscular ® /olume	fL	88.69	(6.11)	77771 8,739	90.06	(5.28)	77771 7,691
Red Cell Distribution Width	%	13.26	(1.24)	77771 8,609	13.06	(0.95)	77771 7,596
Systolic⊞lood®ressure	mm/Hg	123.99	(19.40)	777718,882	127.15	(17.17)	77771 8,012

The IKDM Biological Age Algorithm 2 raining Sample Included Imen Band Iwo men Baged 30-75 Imparticipating In In Industrial III Band II Band III Ba

Appendix Table A.2: Klemera-Doubal Biological Age Algorithm Parameters estimated from the NHANES training sample. The table reports the K, Q, S, and R parameters of the Klemera-Doubal Algorithm. These correspond to the model slope, intercept, root mean squared error, and R-squared for the regressions of the biomarkers on chronological age in the NHANES reference sample. S_{BA}^2 corresponds to the squared variance in chronological age explained by the biomarker panel in the reference sample. The reference population consisted of men and women aged 30-75 years participating in NHANES III and continuous NHANES panels collected during 2003-2016 (N=38,028, 49% male). Pregnant women were excluded.

		Woi	men			M	en	
	K	Q	S	R	K	Q	S	R
Albumin	-0.001	4.169	0.316	0.001	-0.007	4.663	0.303	0.076
Alkaline Phosphatase ¶Log)	0.006	3.903	0.307	0.059	0.002	4.160	0.284	0.005
Blood Turea Nitrogen	0.144	4.327	4.252	0.159	0.096	8.255	4.526	0.070
Creatinine (Log)	0.002	0.471	0.096	0.056	0.001	0.617	0.101	0.031
C-Reactive Protein (Log)	0.008	-1.704	1.148	0.008	0.011	-2.228	1.067	0.016
Glycated⊞emoglobin	0.021	4.560	0.909	0.080	0.018	4.744	0.980	0.055
Uric Acid Log)	0.004	1.518	0.209	0.065	0.000	1.935	0.187	0.000
Lymphocyte®ercent	0.001	30.824	8.266	0.000	-0.101	34.786	8.291	0.024
WhiteBloodCellCountQLog)	-0.002	2.173	0.252	0.008	-0.001	2.105	0.247	0.001
Mean Corpuscular Volume	0.068	86.272	6.038	0.021	0.062	87.974	5.170	0.023
Red Cell Distribution Width	0.004	12.658	1.192	0.002	0.017	11.808	0.864	0.056
Systolic⊞lood®ressure	0.685	91.050	16.940	0.213	0.400	106.016	16.040	0.095
SBA2		176	5.08			212	27	

Homeostatic Dysregulation

We calculated NHANES participants' homeostatic dysregulation using the approach described by Cohen and colleagues (Cohen et al., 2014; Li et al., 2015). Homeostatic dysregulation quantifies deviation of a person's physiology from a reference norm based on biomarker Mahalanobis distance (Mahalanobis, 1936). We computed parameters for the homeostatic dysregulation algorithm based on the same twelve biomarkers used to calculate the Klemera-Doubal Biological Age algorithm. We formed the reference norm from young, healthy participants in NHANES III and Continuous NHANES panels spanning 2003-2014. From these NHANES panels, we selected participants aged 20-30 years who were not obese and whose biomarker values fell within the age- and sex-specific normal range (Appendix Table A.3). Distributions of biomarkers in this young, healthy reference sample are reported in Appendix Table A.4. We standardized all biomarkers to have mean=0, SD=1 within sex and computed the biomarker variance-covariance matrix (Appendix Table A.5). Biomarker means and standard deviations in the reference sample and the standardized-biomarker variance-covariance matrix, together with the Mahalanobis distance equation (Mahalanobis, 1936) formed the homeostatic dysregulation algorithm.

Appendix Table A.3: Ranges of biomarker values used to restrict reference population for training the Homeostatic Dysregulation Algorithm.

	Units of		
	Measure	Women	Men
Albumin	g/dL	3.5-	5.0
Alkaline Phosphatase	U/L	37-98	45-115
Blood Urea Nitrogen	mg/dL	6-21	8-24
Creatinine	mg/dL	0.6-1.1	0.8-1.3
C-Reactive Protein	mg/dL	<	2
Glycated Hemoglobin	%	4.0-	5.6
Total Cholesterol	mg/dL	<2	00
Uric Acid	mg/dL	2.7-6.1	3.7-8.0
Lymphocyte Percent	%	28-	55
White Blood Cell Count	SI	<1	.1
Mean Corpuscular Volume	fL	77-	93
Systolic Blood Pressure	mm/Hg	<1	20
* From http://www.mayom	edicallabora	ntories.com/	

Appendix Table A.4: Biomarker descriptive statistics for the reference population used to define the Homeostatic Dysregulation Algorithm.

			Women			Men	
	Units of 2						
Biomarker	Measure	M	SD	N	M	SD	N
Albumin	g/dL	4.21	(0.30)		4.46	(0.25)	
Alkaline Phosphatase	log@U/L	4.13	(0.23)		4.32	(0.22)	
BloodTureaTNitrogen	mg/dL	10.99	(2.90)		13.46	(3.38)	
Creatinine	log@mg/dL	0.60	(0.07)		0.71	(0.07)	
C-Reactive Protein	log@mg/dL	-1.86	(1.05)		-1.98	(1.01)	
Glycated⊞emoglobin	%	5.03	(0.29)	643	5.12	(0.32)	495
Uric⊠Acid	log@mg/dL	1.62	(0.14)	043	1.88	(0.14)	493
Lymphocyte⊞ercent	%	36.45	(6.13)		36.19	(5.83)	
White Blood Cell Count	log ∄ l	1.99	(0.21)		1.98	(0.21)	
Mean Corpuscular Volume	fL	88.17	(3.32)		88.57	(2.91)	
Red Cell Distribution Width	%	12.65	(0.89)		12.49	(0.57)	
Systolic B lood P ressure	mm/Hg	105.14	(7.44)		111.03	(5.61)	

The Homeostatic Dysregulation Algorithm Reference Sample Included Imen And Swomen Aged 20-30 To Inches NHANES III And Incontinuous INHANES Panels If rom 2003-2016 With BMI 30. Pregnant women Were Excluded. IM: Imean; SD: It and India deviation; IN: It ample It is a market by the India deviation of the India deviation.

Appendix Table A.5: Biomarker Variance Covariance Matrix for the reference population used to define the Homeostatic Dysregulation Algorithm. Biomarkers were standardized to Mean=0, Stand Deviation=1 by sex prior to computing the variance covariance matrix.

	Albumin	Alkaline® Phosphatase	Blood l real	Creatinine	C-Reactive® Protein	Glycated? Hemoglobin	Urid≱cid	Lymphocyte? Percent	White噩lood® Cell©ount	Mean® Corpuscular® Volume	Red©Cell® Distribution® Width	Systolic⊞lood☑ Pressure
Women												
Albumin	1.39	0.08	0.11	0.08	-0.66	-0.28	0.01	0.35	-0.21	0.00	-0.28	-0.31
Alkaline Phosphatase Log)	0.08	3.11	-0.20	-0.50	-0.20	0.32	0.22	0.24	0.12	-0.49	0.06	-0.28
Blood Turea Initrogen	0.11	-0.20	2.54	1.35	0.20	1.01	0.84	0.02	-0.16	0.36	0.11	1.71
Creatinine (Log)	0.08	-0.50	1.35	2.35	0.15	0.75	1.00	0.14	-0.29	0.27	0.16	1.47
C-Reactive®rotein@Log)	-0.66	-0.20	0.20	0.15	1.58	0.75	0.48	-0.44	0.41	-0.01	0.27	1.04
Glycated⊞emoglobin	-0.28	0.32	1.01	0.75	0.75	6.89	0.83	0.28	0.09	-0.27	0.40	2.63
UricAcida(Log)	0.01	0.22	0.84	1.00	0.48	0.83	2.38	0.08	0.03	-0.03	0.16	1.25
Lymphocyte®ercent	0.35	0.24	0.02	0.14	-0.44	0.28	0.08	1.98	-0.80	-0.15	-0.06	-0.04
WhiteBloodCellCountQLog)	-0.21	0.12	-0.16	-0.29	0.41	0.09	0.03	-0.80	1.52	-0.06	0.04	-0.16
Mean Corpuscular Volume	0.00	-0.49	0.36	0.27	-0.01	-0.27	-0.03	-0.15	-0.06	2.74	-0.90	0.47
Red Cell Distribution Width	-0.28	0.06	0.11	0.16	0.27	0.40	0.16	-0.06	0.04	-0.90	1.37	0.42
Systolic ® lood ® ressure	-0.31	-0.28	1.71	1.47	1.04	2.63	1.25	-0.04	-0.16	0.47	0.42	8.49
Men												
Albumin	1.48	0.26	-0.31	-0.35	-0.53	-0.92	-0.02	0.07	0.03	-0.13	-0.47	-0.92
Alkaline Phosphatase Log)	0.26	4.25	-0.66	-1.49	-0.45	-0.49	-0.40	0.45	0.02	-0.98	-0.03	-1.63
Blood@Urea@Nitrogen	-0.31	-0.66	1.76	1.02	0.28	0.69	0.27	-0.32	0.09	0.31	0.20	0.81
Creatinine (Log)	-0.35	-1.49	1.02	2.77	0.32	0.54	0.72	-0.33	-0.02	0.52	0.32	1.31
C-Reactive®rotein@Log)	-0.53	-0.45	0.28	0.32	1.48	0.81	0.35	-0.49	0.41	0.11	0.39	1.07
Glycated⊞emoglobin	-0.92	-0.49	0.69	0.54	0.81	6.96	-0.15	-0.20	0.29	-0.09	0.57	1.82
Uric@Acid@Log)	-0.02	-0.40	0.27	0.72	0.35	-0.15	1.74	-0.14	0.16	-0.03	0.09	0.55
Lymphocyte⊡ercent	0.07	0.45	-0.32	-0.33	-0.49	-0.20	-0.14	2.08	-0.66	-0.26	-0.13	-0.66
WhiteBloodCellCountQLog)	0.03	0.02	0.09	-0.02	0.41	0.29	0.16	-0.66	1.44	0.02	0.06	0.23
Mean Corpuscular Volume	-0.13	-0.98	0.31	0.52	0.11	-0.09	-0.03	-0.26	0.02	3.01	-0.45	0.78
Red Cell Distribution Width	-0.47	-0.03	0.20	0.32	0.39	0.57	0.09	-0.13	0.06	-0.45	1.68	0.79
Systolic Blood Pressure	-0.92	-1.63	0.81	1.31	1.07	1.82	0.55	-0.66	0.23	0.78	0.79	9.42

Appendix Table A.6: Biomarker summary statistics for the NHANES analysis sample. The NHANES analysis sample included women and men aged 20-84 participating in the 1999-2000 and 2001-2002 panels of the Continuous NHANES for whom Klemera-Doubal Biological Age, Homeostatic Dysregulation, and Telomere Length measures were available.

		Women	(N=3,250)	Men (N	=3,481)
	Units of				
Biomarker	Measure	M	SD	M	SD
Albumin	g/dL	4.27	(0.29)	4.44	(0.31)
Alkaline Phosphatase	U/L	74.52	(26.05)	77.23	(24.15)
Blood Urea Nitrogen	mg/dL	13.30	(4.61)	14.97	(4.71)
Creatinine	mg/dL	0.70	(0.20)	0.93	(0.23)
C-Reactive Protein	mg/dL	0.51	(0.68)	0.36	(0.67)
Glycated Hemoglobin	%	5.52	(0.87)	5.59	(0.93)
Uric Acid	mg/dL	4.77	(1.31)	6.07	(1.32)
Lymphocyte Percent	%	30.95	(8.08)	29.64	(8.35)
White Blood Cell Count	SI	7.22	(2.00)	7.02	(1.97)
Mean Corpuscular Volume	fL	89.68	(5.37)	90.74	(4.91)
Red Cell Distribution Width	%	12.74	(1.07)	12.61	(0.81)
Systolic Blood Pressure	mm/Hg	126.30	(22.76)	126.95	(17.92)
Logged Biomarker Values					
Alkaline Phosphatase		4.27	(0.32)	4.32	(0.29)
Creatinine		0.53	(0.11)	0.65	(0.11)
C-Reactive Protein		-1.35	(1.25)	-1.76	(1.20)
Uric Acid		1.73	(0.22)	1.94	(0.19)
White Blood Cell Count		2.08	(0.24)	2.05	(0.24)

Values summarized for n=6,754 individuals aged 20-85 with biomarker and telomere data. M: mean; SD: standard deviation

Appendix B: Construction of Healthspan-related Characteristics and Life-course Risk Factors Construction of Measures for Healthspan-related Characteristics

To conduct validation testing of our biological age measures, we selected a panel of NHANES functional assessments of capacities known to decline with advancing chronological age. These outcomes encompassed three domains: physical functioning, perceptual and cognitive functioning, and subjective functioning and pain.

Physical functioning was assessed using tests of balance, muscle strength (knee extensor peak force), gait speed, and cardiorespiratory fitness (VO₂ Max). We assessed balance using a composite variable which captured variability in participants performance on the Romberg Test of Standing Firm and Compliant Support Surfaces (Weber). Briefly, this test assesses participants ability to stand unassisted under four increasingly difficult conditions. Test Condition 1 requires participants stand with both feet together on a firm surface for 15 seconds with eyes open. Test Condition 2 requires participants stand with both feet together on a firm surface for 15 seconds with eyes closed. Test Condition 3 requires participants stand with both feet together on a compliant surface (foam pad) for 30 seconds with eyes open. Test Condition 4 requires participants stand with both feet together on a compliant surface (foam pad) for 30 seconds with eyes closed. Participants are allowed a maximum of two attempts per conditions. Those who fail both attempts of earlier conditions do not continue to more difficult trials. Less than 5% of the eligible sample failed to progress to Test Condition 4. Our composite variable emphasized performance in Test Condition 4 (NHANES items BAXPFC41 & BAXPFC42). Specifically, our final analytical construct for balance was a dichotomous variable which distinguished between participants who passed Test Condition 4 and those who failed Test Condition 4 or failed both attempts at an earlier trial (Test Conditions 1-3).

Participants' muscle strength was assessed using a Kin Com MP dynamometer to evaluate isokinetic knee extensor strength, and recorded as peak torque (N/m) of the quadriceps at 60°/s. Our final analytical construct was the maximum peak force recorded for each participant (NHANES item MSDAPF). Our final analytical construct for gait speed was participants' time in seconds to complete a 20ft walk (NHANES item MSXWTIME). Cardiovascular fitness was assessed during a submaximal exercise test. Participants' were assigned one of eight treadmill test protocols based on their gender, age, body mass index, and self-reported physical activity. Each protocol includes a 2-minute warm-up, two 3-minute exercise stages, and a 2-minute cool down designed to elicit a heart rate response of 75% their age-predicted maximum. Our final analytical construct for cardiovascular fitness is estimated maximal oxygen update (VO₂ Max; NHANES item CVDESVO₂).

Perceptual and cognitive functioning was assessed using tests of visual acuity, audiometry, and the digit symbol coding task from the Wechsler Adult Intelligence Scale (WAIS III). Participants' visual acuity was assessed as presenting distance visual acuity using their usual correction, if any (e.g. glass/contacts or none). Visual acuity for each eye is recorded in units of Snellen visual acuity (e.g. 20/20; NHANES items VIDRVA & VIDLVA). Participants' Snellen visual acuity was converted to LogMAR units (log of the minimum angle of resolution) to provide a robust measure of visual acuity (Holladay, 1997). Our final analytical construct for visual acuity was the average visual acuity across both eyes in LogMAR units. Audiometry testing was conducted using an Interacoustics Model AD226 audiometer with standard TDH-39 headphones and Etymotic EarTone 3A insert headphones. Hearing threshold testing was conducted on both ears at seven frequencies across the range of human hearing (500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz). Signal intensity varied from -10 to as high as 120 decibels as was recorded as the lowest decibel participants could hear a given frequency (NHANES items AUXU500(L/R), AUXU1K2(L/R), AUXU2K(L/R), AUXU3K(L/R), AUXU4K(L/R),

AUXU6K(L/R), & AUXU8K(L/R)). To reduce audiometry performance to a single measure we conducted principal component analysis across all 16 items within the sample which also had all 3 biological age measures (N=2821). The item mapped to a single component with eigenvalue greater than 1 and which explained 62% of the variance across all 16 items. We extracted regression factor scores for the full sample as well as for men and women independently to use as our final analytical contrast for audiometry. Participants' cognitive functioning was assessed using the digit symbol coding task from the WAIS III. In this task participants must copy symbols that are paired with numbers using a provided key. Our final analytical construct for cognitive functioning was the number of items drawn correctly in 120 seconds (NHANES item CFDRIGHT).

Subjective functioning was assessed using measures of self-reported disability (activities of daily living, ADLs), self-rated general health, and self-reported pain. Self-reported disability was assessed using participants' responses to the Physical Functioning Questionnaire in which participants report experiencing "no difficulty", "some difficulty", "much difficulty", or "unable to do so" for various activities. The questionnaire was assessed for all participants aged 60 or older and those who were aged 20-59 who reported experiencing limitations that kept them from work. For the current analyses, we restricted our sample to only those aged 60 -84. ADLs emphasize day to day actions necessary for personal care such as getting out of bed and dressing oneself. The full list of items included in the ADL domain are reported difficulty walking a quarter mile (NHANES item PFQ060b), walking up ten steps (NHANES item PFQ060c), stooping, crouching, or kneeling (NHANES item PFQ060d), lifting or carrying 10 pounds (NHANES item PFQ060e), walking between rooms on the same floor (NHANES item PFQ060h), standing up from an armless chair (NHANES item PFQ060i), getting in and out of bed (NHANES item PFQ060j), dressing oneself (NHANES item PFQ060l), standing for long periods (NHANES item PFQ060m), sitting for long

periods (NHANES item PFQ060n), and difficulty reaching up over your head (NHANES item PFQ060o). IADLs are similar activities considered to be important for normal functioning, but which are not necessarily related to personal care such as managing money and performing house chores. The full list of items included in the IADL domain are difficulty managing money (NHANES item PFQ060a), performing household chores (NHANES item PFQ060f), preparing meals (NHANES item PFQ060g), using utensils (NHANES item PFQ060k), and grasping or holding small objects (NHANES item PFQ060p). Coding for individual items was performed as previously described (Cook et al 2006 J Disability & Rehab). Specifically, individuals reporting "much difficulty" or "unable to do so" for a given task were coded as being limited for that task. Our final analytical constructs for ADLs and IADLs were three-level variables which distinguished between those with 0 limitations, 1 limitation, or 2+ limitations within the ADL and IADL domains respectively. Participants' self-rated health was assessed based on participant responses when asked to describe their general health (NHANES item HUQ010). Our final analytical construct was incrementally coded to distinguish between those who reported "excellent", "very good", "good", "fair", or "poor" general health.

Self-reported pain was assessed using responses from the NHANES miscellaneous pain questionnaire (MPQ) which collected information on the location and duration of self-reported pain. Participants were asked to distinguish between joint pain and general, miscellaneous pain. We assessed joint pain using a composite variable which combined participants' responses when asked about pain at 16 joint sites across the body (NHANES items MPD050a-q). Our final analytical construct for joint pain distinguished between those with and those without joint pain. Joint pain was defined as reporting pain at any of the 16 sites assessed. A lack of joint pain was defined as reporting no pain across all 16 sites. Chronic pain was defined as previously described (Hardt et al., 2008) using participants' self-reported general pain. Participants were first asked if they had a problem with pain in the last month (NHANES

item MPQ100). Those responding yes were then asked about the duration of pain (NHANES item MPQ110) and to indicate which of 32 body regions were affected using a visual aide (NHANES items MPQ120a-af). Here we defined chronic pain according to College of Rheumatology criteria as pain lasting 3 or more months (Wolfe et al., 1990). For those participants reporting chronic pain we distinguished between widespread and localized chronic pain according to American College of Rheumatology criteria. Specifically, pain was widespread if it was experienced above and below the waist, on both sides of the body, and at one or more axial locations (spine, chest, upper or lower back). Our final analytical construct for chronic pain was a dichotomous variable which distinguished between those with no chronic pain and those with widespread chronic pain.

Appendix Table B.1: Healthspan-related characteristics. For continuous measures, mean and standard deviation are provided. For dichotomous measures, the % with a value of 1 is indicated. For categorical measures, the % with each value of the category is indicated.

						Correlation with
	Mean/%	(SD)	% Male	N	Age Range	Chronological Age
Phyical Functioning						
Cardiorespiratory Fitness (VO2max)	40.49	(10.24)	52%	1,845	20-49	-0.10
Poor Balance	39%		52%	2,746	40-84	0.43
Gait Speed	6.76	(2.87)	52%	3,046	50-84	0.29
Strength	278	(98)	52%	2,412	50-84	-0.38
Cognitive & Perceptual Functioning						
Cognitive Function	43.33	(18.53)	51%	2,035	60-84	-0.22
Hearing	0.05	(1.01)	52%	2,613	20-69	0.58
Vision	0.14	(0.19)	52%	6,474	20-84	0.24
Subjective Functioning/ Disability						
Self-rated Health			52%	6,748	20-84	0.19
Excellent	31%					
Very Good	18%					
Good	4%					
Fair	15%					
Poor	23%					
Activities of Daily Living (ADLs)			51%	2,297	60-84	0.10
0	69%					
1	10%					
2+	21%					
Instrumental Activities of Daily Living (L	ADLs)		51%	2,297	60-84	0.11
0	87%					
1	8%					
2+	5%					
Pain						
Joint Pain	44%		52%	6,722	20-84	0.18
Chronic Pain	3%		52%	6,747	20-84	0.04
<u> </u>						

Construction of Measures for Life-course Risk Factors

To test the hypothesis that accumulating life-course risk would be associated with accelerated biological aging, we selected a panel of NHANES survey assessments of factors known to influence life expectancy and healthspan. Specifically, we assessed educational attainment, material and social resource deficits, and mental health problems.

We assessed educational attainment using self-reported educational attainment for adults aged 20 or older (NHANES item DMDEDUC2). Specifically, our final analytical construct for educational attainment was a four-level variable which distinguished between those with less than a high school degree, those with a high school degree or equivalent but no college experience, those with some college experience, and those with a college degree. Material resources were assessed using poverty income ratio and food security status. Participants' PIR was calculated by dividing family income by poverty guidelines issued by the Department of Health and Human Services (NHANES item INDFMPIR). Since the PIR is top-coded at 5, we restricted our analyses to those participants with PIR 4.99 or below. Participants' food security status is determined based on responses to 10 items in the U.S. Household Food Security Module from the U.S. Department of Agriculture (NHANES item ADFDSEC)(Bickel et al., 2000). Participants' social resources were assessed using a composite variable which combined data from three items in the NHANES social support module (SSQ). Specifically, we combined data from participants' responses to questions about the availability of emotional support (NHANES item SSQ010), need for more emotional support (NHANES item SSQ030), and number of close friends (NHANES item SSQ060). Our final analytical construct for social resources was a dichotomous variable which distinguished between those with and those without social resources. A lack of social resources was defined as reporting no emotional support, reporting a need for more emotional support, or as residing in the lowest quartile for the number of close friends (SSQ060 <= 3). Availability of social resources was coded as reporting available emotional support, reporting no need for more emotional support, and residing in the top three quartiles for the number of close friends (SSQ060 > 3).

Participants' mental health was assessed as previously described (Needham et al., 2015) using a composite variable derived from participants' responses to the NHANES CIDI, an adapted version of three modules from the World Health Organization Composite International Diagnostic Interview, Version 2.1 (CIDI-Auto 2.1) which includes modules for major depression (CIQDEP), generalized anxiety disorder (CIQGAD), and panic disorder (CIQPAN). Our final analytical construct for mental health was a three-level variable which distinguished between those meeting DSM-IV criteria for one or more of major depression (NHANES item CIDDSCOR), generalized anxiety disorder (NHANES item CIDGSCOR), or panic disorder (NHANES item CIDPSCOR), those with depressive or anxious affect, and those with no depressive or anxiety symptoms. Depressive affect was defined as reporting a period of feeling sad, depressed, or empty for two weeks or longer (NHANES item CIQD001). Anxious affect was defined as reporting a period of a month or more in which participants felt worried, tense, or anxious about everyday problems such as work or family (NHANES item CIQG01).

Appendix Table B.2: Life-course Risk Factors. For continuous measures, mean and standard deviation are provided. For dichotomous measures, the % with a value of 1 is indicated. For categorical measures, the % with each value of the category is indicated. SD= standard deviation. N= sample size.

	Mean/%	(SD)	% Male	N	Age Range
Education			52%	6,747	20-84
< High School	33%				
High School Graduate	23%				
Some College	25%				
College Degree	19%				
Poverty	2.71	(1.62)	52%	6,158	20-84
Food Insecurity			52%	6,486	20-84
Secure	81%				
Marginally Insecure	7%				
Insecure without Hunger	8%				
Insecure with Hunger	4%				
Low Social Support	42%		51%	2,295	60-84
Mental Health			51%	1,060	20-39
No anxiety, depression, or					
panic disorder	72%				
Anxious or Depressed Affect	18%				
Diagnosis of Depression,					
Anxiety, or Panic Disorder	10%				

Appendix C: Supplementary Tables and Figures

Appendix Table C.1: Descriptive statistics and correlations among chronological age and biological aging measures in the pooled NHANES 1999-2000 and 2001-2002 samples. All correlations were significant at p < 0.001. M: mean; SD: standard deviation. Panel A shows correlations the measures described in the main text prior to adjustment for chronological age. Panel B shows unadjusted correlations for versions of the KDM Biological Age and homeostatic dysregulation algorithms computed using the same biomarkers as the LM Biological Age.

Panel A.

Tuner 11.						
	M	SD	Chronological Age	KDM Biological Age	Homeostatic Dysregulation	Age Age
Chronologial Age (years)	49.56	(17.77)				
KDM Biological Age (years)	50.14	(18.84)	0.91			
Homeostatic Dysregulation (log units)	3.53	(0.89)	0.56	0.73		
LM Biological Age	34.46	(18.49)	0.96	0.94	0.62	
Telomere Length (log T/S ratio)	0.00	(0.11)	-0.42	-0.39	-0.24	-0.42

Panel B.

	M	SD	Chronological Age	KDM Biological Age	Homeostatic Dysregulation	LM Biological Age
Chronologial Age (years)	49.56	(17.77)				
KDM Biological Age (years)	49.05	(19.08)	0.87			
Homeostatic Dysregulation (log units)	2.80	(0.83)	0.30	0.52		
LM Biological Age	34.46	(18.49)	0.96	0.92	0.42	
Telomere Length (log T/S ratio)	0.00	(0.11)	-0.42	-0.40	-0.16	-0.42

Appendix Table C.2: Associations between biological aging measures and healthspan-related characteristics.

		K	DMBiological 2	lge*	????	Home	eostatic ® ysregi	ulation*	777	LMBiological 2	\ge	777	Telomere Leng	th
	Effect2													
	Size						<u>Effec</u>	t-size 1 r/OR)131195%13C1]13t	-value				
Phyical ⊈ unctioning														
Cardiorespiratory Fitness (VO2max)	r	-0.03	[-0.09] $[-0.03]$	0.288		-0.05	[-0.11] [-0.00]	0.057	-0.11	[-0.17330.05]	0.001	0.05	[0.00] 0.11	0.039
Poor B alance	OR	1.21	[1.11]][1.32]	1.46E-05		1.23	[1.13][1.34]	2.03E-06	1.25	[1.15][1.37]	3.07E-07	0.91	[0.83]]1.00]	0.050
Strength	r	-0.08	[-0.12330.05]	5.28E-06	١.	-0.10	[-0.13]30.06]	0.000	-0.07	[-0.10]30.03]	1.24E-04	0.02	$[-0.02]$ $\boxed{0.06}$	0.258
Gait ® peed	r	-0.15	[-0.19330.12]	1.04E-18		-0.16	[-0.19]30.12]	1.19E-21	-0.15	[-0.18]30.12]	1.11E-20	0.03	[-0.01] $[0.07]$	0.100
Cognitive Perceptual Functioning														
Cognitive function 2	r	-0.13	[-0.17330.10]	8.63E-13	-	-0.14	[-0.18]30.10]	7.25E-12	-0.13	[-0.16]30.09]	8.42E-11	0.04	[-0.01] $[0.08]$	0.124
Hearing	r	-0.07	[-0.09][30.04]	1.64E-07	-	-0.10	[-0.12][30.07]	8.38E-12	-0.10	[-0.13]30.07]	5.68E-12	0.03	[0.00] [0.05]	0.037
Vision	r	-0.11	[-0.15][30.08]	1.69E-11	-	-0.07	[-0.10]30.03]	1.20E-04	-0.11	[-0.15330.07]	2.00E-09	0.02	[-0.01330.05]	0.209
Subjective unctioning/Disability														
Self-rated Health	r	-0.20	[-0.22330.18]	9.96E-61	-	-0.19	[-0.22][30.17]	8.04E-56	-0.21	[-0.24]30.19]	2.56E-68	0.04	[0.02]10.07]	0.002
ADL?	IRR	1.28	[1.22][1.35]	3.10E-21		1.28	[1.2233.35]	3.39E-20	1.26	[1.21][1.32]	8.94E-23	0.95	[0.89][1.02]	0.180
IADL?	IRR	1.45	[1.32][1.58]	1.79E-16		1.43	[1.30][1.58]	3.49E-13	1.36	[1.25][1.47]	1.89E-13	0.97	[0.86]].11]	0.694
Pain														
Joint ⊡ Pain	OR	1.09	[1.04][1.15]	0.001		1.04	[0.9931.09]	0.146	1.14	[1.08][1.20]	4.62E-07	0.97	[0.9231.03]	0.351
Chronic Pain	OR	1.29	[1.17][1.43]	0.000		1.22	[1.09][1.37]	0.001	1.35	[1.23][1.49]	4.11E-10	0.94	[0.82]]1.08]	0.405

For Ithis analysis, IXDM Biological Age and Ithomeostatic Dysregulation imeasures awere to mputed using Ithe Bame Biological action to makers as each of the Biological action in the Biological act

Appendix Table C.3: Sex-differences in associations between biological aging measures and healthspan-related characteristics

			ı	KDM B iological	Age I	mm Hor	neostatic Dysre	gulation	777	LMBiological	Age	777	Telomere Leng	th
		Effect- Size					Effect-size 1	b⊉lnOR⊉₫r	nIRR)∰95%[CI]D-value				
Phyical Functioning									-					
Cardiorespirator	MainŒffectℚwomen)	b	-0.07	[-0.15] [0.02]	0.110	-0.1	4 [-0.23閏0.04]	0.004	-0.15	[-0.23]	7.53E-05	0.03	[-0.04]30.10]	0.430
y I fitnessI	Interaction (sex difference)	b	-0.02	[-0.15]30.11]	0.784	0.0	8 [-0.05] [30.21]	0.214	0.11	[-0.02]10.23]	0.095	0.05	[-0.05]0.15]	0.314
Poor ® alance	MainŒffect頃women)	In(OR)	0.10	[-0.02]10.22]	0.115	0.1	5 [0.0130.29]	0.030	0.14	[0.02]10.27]	0.026	-0.11	[-0.24][0.02]	0.100
	Interaction (sex difference)	III(OK)	0.08	[-0.09]30.25]	0.358	0.1	1 [-0.08@30.30]	0.253	0.16	[-0.01]30.33]	0.071	0.03	[-0.15]30.22]	0.720
Strength	MainŒffect頃women)	b	0.05	[0.00]	0.073	-0.0	1 [-0.0720.05]	0.684	-0.03	[-0.08]	0.337	0.02	· [-0.04@0.08]	0.468
	Interaction (sex difference)	D	-0.12	[-0.19]30.05]	4.81E-04	-0.0	9 [-0.17🖫0.01]	0.030	-0.08	[-0.15]	0.035	0.00	[-0.07]]].08]	0.915
Gaitßpeed	MainŒffect頃women)	b	-0.10	[-0.15][0.06]	3.58E-05	-0.1	4 [-0.19@@0.08]	1.65E-07	-0.17	[-0.22🖫0.12]	3.95E-13	0.02	[-0.03]30.06]	0.485
	Interaction (sex difference)	D	0.02	[-0.05]	0.601	-0.0	1 [-0.08] [-0.08]	0.716	0.03	[-0.03330.10]	0.310	0.03	[-0.04]]	0.424
Cognitive & Percept	tual@unctioning													
CognitiveFunction	〖MainŒffect頃women)	b	-0.17	[-0.21][0.12]	1.61E-12	-0.2	7 [-0.34🖫0.20]	3.77E-14	-0.16	[-0.22]30.11]	3.99E-09	0.05	[-0.02]30.11]	0.138
	Interaction (sex difference)	D	0.07	[0.00]10.14]	0.054	0.0	6 [-0.04月10.16]	0.218	0.07	[-0.01] [0.14]	0.081	-0.02	[-0.11]30.07]	0.630
Hearing	MainŒffectī(women)	b	-0.07	[-0.11]30.03]	7.05E-04	-0.0	9 [-0.130.05]	8.48E-06	-0.10	[-0.14]30.06]	1.44E-06	0.02	[-0.02@0.05]	0.385
	Interaction (sex difference)	, b	-0.01	[-0.07]10.04]	0.670	-0.0	1 [-0.06] [-0.04]	0.781	-0.01	[-0.06]10.05]	0.836	0.02	[-0.02@O.07]	0.359
Vision	MainŒffect頃women)	b	-0.11	[-0.16]30.05]	1.09E-04	-0.0	9 [-0.150.03]	0.002	-0.11	[-0.16]	1.99E-05	0.01	. [-0.03@0.05]	0.655
	Interaction (sex difference)	b	0.01	[-0.06]10.09]	0.716	0.0	1 [-0.06] [10.08]	0.785	0.00	[-0.08]10.07]	0.902	0.02	[-0.04]ID.08]	0.504
SubjectiveFunction	ing/Disability													
Self-rated⊞ealth	MainŒffect頃women)	b	-0.18	[-0.22🖫 0.15]	3.60E-27	-0.2	5 [-0.29PB0.22]	5.98E-41	-0.23	[-0.26🖫 0.19]	1.21E-39	0.04	[0.01330.08]	0.013
	Interaction (sex difference)	~	0.01	[-0.04330.06]	0.642	0.0	0 [-0.04230.05]	0.876	0.03	[-0.02330.07]	0.276	0.00	[-0.05]30.04]	0.850
ADL?	MainŒffect頃women)	In(IRR)	0.13	[0.06]10.19]	1.04E-04		1 [0.11330.31]	2.70E-05		[0.16] [0.29]	3.02E-12		[-0.18]30.00]	0.060
	Interaction (sex difference)	()	0.09	[-0.01330.18]	0.066	0.0	8 [-0.06@0.23]	0.276	0.02	[-0.08]30.11]	0.734	0.09	[-0.05@30.23]	0.216
IADL®	MainŒffect頃women)	In(IRR)	0.15	[0.03] [0.26]	0.012	0.3	6 [0.19@0.53]	3.60E-05	0.36	[0.24] [0.47]	6.36E-10	-0.08	[-0.25]	0.322
	Interaction (sex difference)	()	0.14	[-0.02330.31]	0.086	0.0	7 [-0.18330.32]	0.577	-0.10	[-0.26]	0.253	0.13	[-0.12]30.38]	0.312
Pain														
Joint⊕ain	MainŒffect頃women)	In(OR)	0.11	$[0.04 \ \Box 0.18]$	0.003		2 [0.04] [0.19]	0.004		[0.10] [0.24]	2.66E-06		[-0.12]30.02]	0.172
	Interaction (sex difference)	(٥١١)	-0.04	[-0.14]30.06]	0.409	-0.1	1 [-0.24頁30.04]	0.006	-0.08	[-0.18]10.02]	0.100	0.05	[-0.05]	0.321
Chronic®ain	MainŒffect頃women)	In(OR)	0.20	[0.03] [0.37]	0.019	0.2	6 [0.09@30.44]	0.003	0.34	[0.21]30.47]	3.82E-07	-0.05	[-0.23]30.13]	0.563
	Interaction sex difference)	(٥.١.)	0.00	[-0.23] [10.24]	0.989	-0.0	8 [-0.3100.15]	0.500	-0.08	[-0.26]10.10]	0.383	-0.02	[-0.26] [-0.23]	0.900

All@models@ncluded@covariates@or@main@ffects@bf@ex,@hronological@ge,@and@he@nteraction@between@ex@and@hronological@ge,@biological@ging@measures@vere@standardized@vithin@ex;@coefficients@effect@hange@n@he@butcome@variable@ssociated@vith@@c\$D@ncresase@n@he@biological@ging@measure.@continuous@healthspan-related@haracteristics@standardized@vithin@ex@to@have@M=0,&D=1@or@nalysis@nd@analyzed@vith@inear@egression.@biohotomous@healthspan-related@tharacteristics@vere@nalyzed@vith@ogistic@egression.@eported@ffect-sizes@are@og@odds@atios@lnOR).@count@healthspan-related@tharacteristics@vere@nalyzed@vith@negative@inomial@egression.@eported@coefficients@re@og@ncidence@ate@atios@lnIRR).@

Appendix Table C.4: Associations between biological aging measures and healthspan-related characteristics after adjustment for BMI

		I	KDMBiological	Age	7777 H	meostatic Dysre	gulation	777	LMBiological 2	\ge	777	Telomere Lengt	th
	Effect2												
	Size					<u>Effe</u>	ct-size 1r/O R)27195%(BCI)[ab	-value				
Phyical unctioning													
Cardiorespiratory Titness (VO2max)	r	0.01	[-0.07]10.08]	0.890	-0.0	5 [-0.12] 0.01]	0.106	-0.05	[-0.12] 0.01	0.121	0.04	[-0.01]	0.092
Poor ® alance	OR	1.21	[1.11🖫 .32]	2.89E-05	1.2	9 [1.16][1.42]	9.79E-07	1.32	[1.2033.45]	2.90E-09	0.91	[0.82331.00]	0.040
Strength	r	-0.05	[-0.08]]]0.01]	0.006	-0.0	8 [-0.13]30.04]	1.17E-04	-0.11	[-0.14]30.07]	6.81E-09	0.03	[-0.01]	0.167
Gait®peed	r	-0.07	[-0.10]]]0.04]	1.55E-06	-0.1	2 [-0.16]	1.19E-11	-0.12	[-0.15]30.09]	2.32E-15	0.03	[-0.01]	0.139
Cognitive & Perceptual Functioning													
Cognitive unction 	r	-0.13	[-0.16]30.09]	2.64E-11	-0.2	3 [-0.28]	6.67E-19	-0.12	[-0.16]30.08]	2.31E-08	0.04	[-0.01]	0.121
Hearing	r	-0.08	[-0.11]30.05]	1.91E-08	-0.1	0 [-0.13]30.07]	1.75E-11	-0.10	[-0.13]30.07]	3.80E-12	0.03	$[0.00]$ $\boxed{1}$ $\boxed{0.06}$	0.020
Vision	r	-0.10	[-0.14]30.05]	3.52E-06	-0.0	7 [-0.11][30.03]	7.62E-04	-0.09	[-0.13]30.06]	1.52E-06	0.02	[-0.01] [0.05]	0.265
Subjective Functioning/Disability													
Self-rated@Health	r	-0.14	[-0.17]30.12]	3.50E-29	-0.2	2 [-0.25] [30.19]	1.84E-52	-0.18	[-0.20]30.15]	4.26E-45	0.03	[0.01330.06]	0.008
ADL?	IRR	1.12	[1.06][1.18]	5.04E-05	1.2	2 [1.13🖫 1.32]	5.14E-07	1.20	[1.1433.26]	1.57E-11	0.94	[0.88][1.02]	0.121
IADL?	IRR	1.19	[1.08][1.31]	5.06E-04	1.4	2 [1.24][1.63]	5.36E-07	1.29	[1.1733.42]	1.19E-07	0.98	[0.85][1.12]	0.770
Pain													
Joint ⊡ Pain	OR	1.01	[0.96] [0.96]	0.719	0.9	9 [0.93][1.05]	0.646	1.07	[1.01][1.13]	0.014	0.98	[0.93][1.04]	0.514
ChronicıPain	OR	1.08	[0.95][1.23]	0.222	1.1	4 [0.98][1.32]	0.095	1.24	[1.1127.38]	1.00E-04	0.96	[0.83][1.10]	0.533

Allmodelsancluded avariates for an ain affects by fabody-mass and ex, Bex and achieved allege. Biological aging an easures avered at and ardized avithing ex; a coefficients affect all ference and a count on the abiological aging and an alysed avithance as sociated avithance as sociated avithance and a count and a company and a company and a count and a

Appendix Table C.5: Associations between biological aging measures and healthspan-related characteristics after adjustment for race/ethnicity

		I	KDMBiological	Age	m Ho	meostatic Dysreg	gulation	777	LMBiological 3	Age	m	Telomere Leng	th
	Effect [□]												
	Size					Effec	t-size¶r/OR	()27195%2C1]2a	o-value				
Phyical Functioning													
CardiorespiratoryŒitness	r	-0.06	$[-0.13]$ $\boxed{0}.01$	0.070	-0.07	[-0.14] [30.01]	0.028	-0.10	[-0.16] [-0.03]	0.002	0.07	$[0.02\ 20.12]$	0.011
Poor ® alance	OR	1.14	[1.05][1.24]	0.003	1.21	[1.09][1.34]	1.97E-04	1.25	[1.15][1.37]	5.48E-07	0.91	[0.83]]1.00]	0.048
Strength	r	0.00	[-0.04] $[0.03]$	0.842	-0.04	[-0.08]10.00]	0.065	-0.07	[-0.10月30.03]	3.08E-04	0.02	$[-0.02]$ $\boxed{0.06}$	0.325
Gait ® peed	r	-0.08	[-0.11330.04]	2.03E-05	-0.10	[-0.15][30.06]	6.13E-07	-0.14	[-0.17]30.11]	6.95E-17	0.03	[-0.01]	0.096
Cognitive Benceptual Functioning													
Cognitive unction 2	r	-0.10	[-0.13330.06]	3.81E-09	-0.15	[-0.20] [30.11]	2.42E-11	-0.11	[-0.14]30.07]	1.06E-09	0.03	[-0.01]	0.167
Hearing	r	-0.07	[-0.09330.04]	1.19E-06	-0.08	[-0.11][30.05]	1.37E-07	-0.10	[-0.13]30.07]	5.27E-11	0.03	[0.00] 0.05	0.057
Vision	r	-0.12	[-0.16330.08]	2.75E-10	-0.11	[-0.15][30.07]	4.74E-07	-0.12	[-0.16]30.09]	4.84E-12	0.01	$[-0.02]$ $\boxed{0.04}$	0.461
SubjectiveFunctioning/Disability													
Self-rated⊞ealth	r	-0.17	[-0.19]30.15]	1.66E-46	-0.22	[-0.25][30.19]	6.22E-55	-0.21	[-0.23]30.18]	3.63E-67	0.03	[0.00]][0.05]	0.033
ADL?	IRR	1.19	[1.13][1.25]	9.68E-12	1.27	[1.1841.37]	5.68E-10	1.27	[1.213]1.33]	1.49E-23	0.96	[0.89][1.03]	0.223
IADL?	IRR	1.25	[1.14][1.36]	5.34E-07	1.46	[1.28][1.66]	1.64E-08	1.39	[1.28🖫 .51]	1.34E-14	0.98	[0.87][1.11]	0.802
Pain													
Joint⊞ain	OR	1.10	[1.04][1.15]	3.26E-04	1.07	[1.01][1.14]	0.027	1.14	[1.09][1.20]	2.56E-07	0.96	$[0.91$ $\boxed{2}$ $\boxed{1}.01$	0.134
Chronic	OR	1.22	[1.08][1.37]	0.001	1.26	[1.09🖫 .47]	0.002	1.35	[1.23🖫.49]	8.39E-10	0.92	[0.80][1.06]	0.275

Allmodelsancluded tovariates for main and frects to face/ethnicity, Bexand thronological age. Beiological agengameasures are tandardized within Bex; to efficients are flect difference and outcome as sociated with a Both free common outcome as sociated with a Both free common outcome as sociated with a Both free common of the social and a soc

Appendix Table C.6: Associations between biological aging measures and cognitive & perceptual functioning after adjustment for educational attainment

			VDMB0iological5	N ~ ~	[3999]	Цам	neostatic Dysreg	ulation	[595]	L MEDialogicalE	١~٠	[335)	Talamara Fara	· h
			KDMBiological	Age	7777	Hom	ieostaticabysreg	guiation	777	LMBiological 2	Age	777	Telomere Lengt	tn
	Effect2													
	Size						Effec	t-size 1 r/OI	R)171195%17CI]13	b-value				
Cognitive & Perceptual Functioning														
Cognitive g unction g	r	-0.09	[-0.12330.06]	7.33E-10		-0.15	[-0.20330.11]	2.10E-13	-0.09	[-0.120.05]	1.07E-07	0.01	[-0.03] [0.05]	0.714
Hearing	r	-0.06	[-0.09330.03]	1.24E-05		-0.07	[-0.10330.04]	1.20E-06	-0.09	[-0.11330.06]	3.53E-09	0.01	[-0.01]	0.260
Vision	r	-0.09	[-0.13]30.05]	3.62E-06		-0.05	[-0.09]30.01]	0.010	-0.09	[-0.13]30.06]	3.80E-07	0.01	[-0.02]10.04]	0.585

Allmodelsancludedaovariatesaoramainaeffectsabfaeducationalattainment, Bexandahronologicalage. Beiologicalagingameasuresavereatandardizedavithinaex; acoefficientsaeflectadifferenceanabutcomeassociatedavithadas Daifferenceanaheabiologicalagingameasure. Bootinuousahealthspan-relatedatharacteristicsavereastandardizedavithinaexadoahavean=0, SD=12 for analysisanda nalyzedavithalinearaegression. Bootinuousahealthspan-relatedatharacteristicsavereanalyzedavithalogisticaegression. Reportedaeffect-sizesareaddsaratiosalor). Bootinaequesta healthspan-relatedatharacteristicsavereanalyzedavithalogisticaegression. Proportedaeffect-sizesareaddsaratiosalor). Bootinuousahealthspan-relatedatharacteristicsavereanalyzedavithalogisticaegression. Proportedaeffect-sizesareaddsaratiosalor). Bootinuousahealthspan-relatedatharacteristicsavereanalyzedavithalogisticaegression. Proportedaeffect-sizesareaddsaratiosalor). Bootinuousahealthspan-relatedaeffect-sizesareaddsaratiosalor. Bootinuousahealthspan-relat

Appendix Table C.7: Associations between life-course risk factors and biological aging measures.

	KE	OMBiological A	ge 🌃	1 Home	Homeostatic Dysregulation			L	M B iological A g	ge	777	Telomere 1 ength		
					Effec	ct-size 1 r/OR)団95%	<u>63Cl]3b-va</u>	lue					
Stressors@Hypothesized@to	Accele	rate 2 Aging												
Education	0.13	$[0.11\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	6.11E-27	0.12	$[0.09]$ $\boxed{0.14}$	5.99E-24		0.11	$[0.09]$ $\boxed{0.14}$	2.03E-20	-0.07	[-0.09即30.04]	1.99E-09	
Poverty	0.13	[0.10]]]0.15]	1.59E-24	0.12	$[0.10]$ $\boxed{0.15}$	1.03E-24		0.14	$[0.11]$ $\boxed{0.16}$	1.89E-27	-0.05	[-0.07]30.03]	2.83E-05	
Food nsecurity	0.08	[0.05] [0.11]	4.97E-09	0.06	[0.04] [0.09]	3.14E-07		0.07	$[0.05]$ $\boxed{0.10}$	4.26E-08	-0.02	[-0.04] [10.00]	0.033	
Low S ocial S upport	0.16	[0.07]]]0.25]	6.41E-04	0.22	$[0.13]$ $\boxed{0.31}$	1.11E-06		0.21	$[0.11]$ $\boxed{0.30}$	2.02E-05	-0.04	[-0.12]10.03]	0.251	
Poor ¹ Mental ¹ Health	0.04	[-0.04]10.12]	0.338	0.03	[-0.04] [-0.11]	0.382		0.04	[-0.04] [-0.12]	0.290	0.02	[-0.06]10.10]	0.667	

For this handysis, at DMB iological Age and Homeostatic Dysregulation are as ure solvered computed using the Bame Bib iomarkers used to compute the MB iological Age. Besults for the Bame Bib iomarkers used to compute the MB iological Age. Besults for the Bame Bib iomarkers used to compute the MB iological Age. Besults for the Bame Bib iological Age. Besults for th

Appendix Table C.8: Associations between life-course risk factors and biological aging measures after adjustment for BMI.

	KI	DMBiologicalA	ge	????	Home	ostatic Dysregu	lation	777	L	MBiologicalAg	e	???	Telomere Length		
						Effec	ct-size 1 r/OF	()団95%	6 1 001]	lue					
Stressors Hypothesized	∄o∄Accele	rate 2 Aging													
Education	0.09	[0.06] [0.11]	3.35E-13		0.12	[0.10] [0.14]	1.05E-34		0.09	$[0.07]$ $\boxed{0.11}$	3.17E-14	-0.06	[-0.09]30.04]	6.92E-09	
Poverty	0.09	[0.06] [0.11]	1.06E-12		0.11	[0.09] [0.13]	7.51E-28		0.12	$[0.10]$ $\boxed{0.14}$	2.60E-23	-0.05	[-0.07330.03]	3.66E-05	
Foodansecurity	0.04	[0.01] [0.06]	0.002		0.07	[0.05]	1.72E-10		0.06	[0.04] [0.08]	1.19E-06	-0.02	[-0.04] $[0.00]$	0.042	
Lowsocialsupport	0.12	[0.03] [10.22]	0.012		0.15	[0.08] [0.22]	2.77E-05		0.19	[0.10] [0.29]	3.87E-05	-0.04	[-0.11]10.04]	0.362	
Poor Mental Health	0.01	[-0.06]10.08]	0.802		0.00	[-0.07]]0.06]	0.883		0.04	[-0.03] [10.11]	0.263	0.02	[-0.06] [-0.10]	0.619	

All@models@ncluded@covariates@for@main@ffects@bf@body-mass@index,@ex@and@thronological@age.Bbiological@aging@measures@were@standardized@within@ex@to@have@M=0\\$D=1@for@analysis.@Coefficients@reflect\\$D@cceleration@n@biological@aging@per@init@ncrease@n@the@exposure.@education,@poverty,@and@food-insecurity@exposure@measures@were@standardized@to@have@M=0\\$D=1@for@analysis.@Low@coial@upport@and@ooo@mental@health@are@dichotomous@ndicators.@

Appendix Table C.9: Associations between life-course risk factors and biological aging measures after adjustment for race/ethnicity.

	KI	DMBiologicalA	ge	????	Home	ostatic Dysregu	lation	777	LMBiologicalA	ge	777	Telomere1Lengt	h
						<u>Effec</u>	ct-size@r/OR	77195%(TCI)(Tab	-value				
Stressors Hypothesized I	atoaAccele	rate ® Aging											
Education	0.11	[0.09] [0.14]	1.46E-17		0.11	[0.09]10.13]	1.71E-25	0.12	2 [0.10] [0.15]	1.36E-20	-0.0	5 [-0.07] 3 3 3 3 3 3 3 3 3 3	2.38E-05
Poverty	0.09	[0.06] [0.12]	6.64E-12		0.09	$[0.07]$ $\boxed{0.11}$	1.96E-17	0.14	[0.11] [0.16]	2.58E-24	-0.0	4 [-0.06] [-0.02]	8.17E-04
Food nsecurity	0.03	[0.01] [0.06]	0.006		0.05	[0.03] 0.07	1.69E-06	0.0	7 [0.04] [0.10]	2.79E-07	-0.0	1 [-0.03] [0.01]	0.330
Low\social\support	0.10	$[0.00]$ $\boxed{0.20}$	0.051		0.11	[0.04] [0.18]	0.004	0.18	8 [0.08] [0.27]	3.16E-04	-0.0	4 [-0.12] [-0.04]	0.357
Poor Mental Health	0.01	[-0.07]10.08]	0.843		-0.01	[-0.07]10.06]	0.846	0.04	[-0.04][0.12]	0.311	0.02	[-0.06] [-0.10]	0.670

All@models@ncluded@ovariates@or@main@ffects@bf@ace/ethncity,&ex@and@thronological@ge.@iological@ging@measures@were@tandardized@vithin&ex@o@have@M=0&D=1@for@analysis.@Coefficients@reflect&D@acceleration@n@biological@ging@per@int@ncrease@n@the@exposure.@Education,@overty,@and@food-insecurity@exposure@measures@vere@standardized@to@have@M=0&D=1@for@analysis.@Low&ocial@upport@and@oor@mental@health@are@dichotomous@ndicators.@

Appendix Table C.10: Associations between biological aging measures and healthspan-related characteristics: Effect-sizes for biological aging measures computed without and with leukocyte telomere length. Analysis includes data only from NHANES 1999-2000 (NHANES 2001-2002 used to train telomere parameters for biological aging algorithms).

		- 1	KDMBiological	Age	????? K	DM Biologica	l@Age@w/@LTL	777	lome	eostatic D ysreg	ulation	T Homeot	:atic Dysregulat	ion3w/1LTI
	Effect ²													
	Size						Effect-size 1r/C	R)11195%11	CI]@b-	value				
Phyical Functioning														
Cardiorespiratory Iness (VO2max)	r	-0.08	$[-0.18]$ $\boxed{0.02}$	0.119	-0.	L2 [-0.21]]BC	0.02] 0.013	-0.	.05	[-0.15] [0.05]	0.285	-0.06	$[-0.16]$ $\boxed{1}$ $\boxed{1}$ $\boxed{1}$	0.214
Poor B alance	OR	1.42	[1.19🖫.70]	1.28E-04	1.4	6 [1.22]	.75] 4.81E-05	1.	30	[1.08][1.56]	0.005	1.30	[1.08][1.56]	0.006
Strength	r	0.00	[-0.05]10.06]	0.917	-0.	0.0833	.03] 0.374	-0.	.06	$[-0.12]$ $\boxed{0.00}$	0.062	-0.07	[-0.14][0.01]	0.026
Gait s peed	r	-0.09	[-0.13]30.04]	9.88E-05	-0.	LO [-0.15]]BC	0.05] 2.02E-05	-0.	.14	[-0.20]30.09]	1.34E-07	-0.15	[-0.20]30.09]	8.20E-0
Cognitive & Perceptual Functioning														
Cognitive unction 2	r	-0.13	[-0.18]30.08]	1.26E-06	-0.	L4 [-0.20]BC	0.09] 3.36E-07	' -0.	.21	[-0.28]30.14]	1.03E-08	-0.22	[-0.30][30.15]	1.95E-0
Hearing	r	-0.09	[-0.13]30.05]	4.75E-05	-0.)9 [-0.13¤©	0.05] 1.28E-05	-0.	.11	[-0.16]330.06]	2.83E-06	-0.12	[-0.16][0.07]	3.69E-07
Vision	r	-0.10	[-0.16]30.04]	9.28E-04	-0.)9 [-0.15¤©	0.001	-0.	.09	[-0.15]30.03]	0.004	-0.09	[-0.15][0.03]	0.004
Subjective Functioning / Disability														
Self-rated⊞ealth	r	-0.16	[-0.19]30.12]	4.11E-19	-0.	.7 [-0.21��C	0.14] 5.17E-23	-0.	.23	[-0.27]30.19]	9.28E-29	-0.23	[-0.27]30.19]	3.42E-3
ADL?	IRR	1.19	[1.11][1.27]	3.64E-07	1.2	0 [1.12]	.29] 5.01E-07	1.	29	[1.17🖫 .43]	8.62E-07	1.30	[1.18🖫.44]	3.46E-07
IADL?	IRR	1.27	[1.13][1.44]	8.81E-05	1.2	9 [1.13]	.47] 1.64E-04	1.	49	[1.25][1.77]	1.00E-05	1.49	[1.24][1.79]	1.99E-0
Pain														
Joint ⊡ Pain	OR	1.05	[0.98]1.13]	0.140	1.0	7 [1.00][1	.15] 0.059	1.	01	[0.93][1.10]	0.803	1.02	[0.93][1.11]	0.696
ChronicıPain	OR	1.26	[1.05][1.50]	0.013	1.3	0 [1.08]	.56] 0.005	1.	34	[1.09][1.66]	0.006	1.42	[1.14][1.75]	0.001

All@models@ncluded@covariates@for@main@effects@f@ex@and@thronological@ge.Biological@ging@measures@were@tandardized@within@ex;@coefficients@effect@difference@n@utcome@associated@with@@coefficients@effect@difference@n@utcome@associated@with@@coefficients@effect@difference@n@officients@effect@difference@n@officients@effect@difference@n@coefficients@effect@with@coefficients@were@tandardized@within@ex@coeffacet@coefficients@effects@were@tandardized@within@ex@coeffacet@coefficients@effects@coefficients@effects@

Appendix Table C.11: Associations between life-course risk factors and biological aging composite scores. Analysis includes data only from NHANES 1999-2000 (NHANES 2001-2002 used to train telomere parameters for biological aging algorithms).

HOIII THIN II LED T.		9 (1 1111 11 12 2		<i>y</i> = c		***************************************	10 p 001 00111		7	8	8 418 911		- / -		
	K	DMBiological 🕸	ge	3777	KDM	Biological3Age3	w/aLTL	777	Home	ostatic Dysregu	ılation	777	Homeostatic Dysregulation w		
						Effe	ct-size@r/OF	()団95%	⊡CI] ⊡b-va	lue					
Stressors Hypothesize	ditoiAccele	rate A ging													
Education	0.11	[0.08] 0.13	1.73E-18		0.13	[0.11730.16]	1.58E-28		0.13	$[0.11\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	2.26E-39		0.13	[0.11]]]0.15]	3.96E-37
Poverty	0.10	[0.08] 0.13	3.11E-16		0.12	$[0.10]$ $\boxed{0.15}$	2.40E-22		0.12	$[0.10\] \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	7.59E-32		0.12	[0.10]]]0.14]	3.25E-32
Food nsecurity	0.04	[0.02] 10.06]	8.94E-04		0.06	[0.03] [0.08]	5.79E-06		0.07	[0.05]	1.41E-11		0.07	[0.05]]]0.09]	2.39E-11
LowsSocialsSupport	0.16	[0.06] [0.26]	0.002		0.17	[0.07]10.26]	6.63E-04		0.17	[0.10] [0.24]	2.17E-06		0.20	[0.13]]]0.27]	2.40E-08
Poor Mental Health	0.01	[-0.06]	0.796		0.00	[-0.08]	0.995		-0.01	[-0.07] [-0.06]	0.853		-0.01	[-0.08]10.06]	0.832

All@models@ncluded@covariates@for@main@ffects@bf&ex@and@thronological@age.@biological@aging@measures@were&tandardized@within&ex@to@have@M=0&D=1@for@analysis.@Coefficients@reflect&D@cceleration@n@biological@aging@per@unit@ncrease@n@the@exposure.@cducation,@poverty,@and@food-insecurity@exposure@measures@were&tandardized@co@have@M=0&D=1@for@analysis.@Low@coial@upport@and@poor@mental@health@re@lichotomous@ndicators.@

Appendix Table C.12 Associations of KDM Biological Age, homeostatic dysregulation, and LM Biological Age measures computed from the same biomarkers with healthspan-related characteristics. For this analysis, KDM Biological Age and homeostatic dysregulation measures were computed from the same set of biomarkers included in the LM Biological Age.

		K	DMBiologicalAg	e*	7777	Home	ostatic ® ysregul	ation*	???		LMBiologicalAg	ge
	Effect2					Effect-size	e@ir/OR)@195%@CI]⊉o-value	_			
Phyical Functioning												
CardiorespiratoryŒitness頃VO2max)	r	-0.03	[-0.09]10.03]	0.288		-0.05	$[-0.11]$ $\boxed{0.00}$	0.057		-0.11	[-0.17330.05]	0.001
Poor⊞alance	OR	1.21	[1.11771.32]	1.46E-05		1.23	[1.13][1.34]	2.03E-06		1.25	[1.15][1.37]	3.07E-07
Strength	r	-0.08	[-0.12][30.05]	5.28E-06		-0.10	[-0.13]30.06]	1.55E-07		-0.07	[-0.10]30.03]	1.24E-04
Gaitßpeed	r	-0.15	[-0.19] [30.12]	1.04E-18		-0.16	[-0.19]30.12]	1.19E-21		-0.15	[-0.18330.12]	1.11E-20
Cognitive Perceptual Functioning												
Cognitive unction 2	r	-0.13	[-0.17]30.10]	8.63E-13		-0.14	[-0.18]30.10]	7.25E-12		-0.13	[-0.16330.09]	8.42E-11
Hearing	r	-0.07	[-0.09]30.04]	1.64E-07		-0.10	[-0.12330.07]	8.38E-12		-0.10	[-0.13330.07]	5.68E-12
Vision	r	-0.11	[-0.15][30.08]	1.69E-11		-0.07	[-0.10]30.03]	1.20E-04		-0.11	[-0.15330.07]	2.00E-09
Subjective Functioning/Disability												
Self-rated ® Health	r	-0.20	[-0.22]30.18]	9.96E-61		-0.19	[-0.22330.17]	8.04E-56		-0.21	[-0.24330.19]	2.56E-68
ADL?	IRR	1.28	[1.2237.35]	3.10E-21		1.28	[1.22][1.35]	3.39E-20		1.26	[1.2137.32]	8.94E-23
IADL®	IRR	1.45	[1.3237.58]	1.79E-16		1.43	[1.30][1.58]	3.49E-13		1.36	[1.25][1.47]	1.89E-13
Pain												
JointıPain	OR	1.09	[1.043][1.15]	0.001		1.04	[0.99]].09]	0.146		1.14	[1.083] [1.20]	4.62E-07
ChronicıPain	OR	1.29	[1.17]1.43]	3.47E-07		1.22	[1.09] [1.37]	0.001		1.35	[1.23][1.49]	4.11E-10

Forethisanalysis, and Mariological and angular measures angular measure

Appendix Table C.13 Associations of life-course risk factors with KDM Biological Age, homeostatic dysregulation, and LM Biological Age measures computed from the same biomarkers. For this analysis, KDM Biological Age and homeostatic dysregulation measures were computed from the same set of biomarkers included in the LM Biological Age.

		KDM B iological	Age	7777	Hom	eostatic ® ysreg	ulation	777	LM B iological A ge			
				<u> </u>	Effect-siz	e@r/OR)295%3	CI]�p-value	_				
Stressors Hypothesize	ditoiAc	celerate Aging										
Education	0.13	[0.11	6.11E-27		0.12	[0.09] $[0.14]$	5.99E-24		0.11	[0.09] [0.14]	2.03E-20	
Poverty	0.13	[0.10] $0.15]$	1.59E-24		0.12	$[0.10\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $	1.03E-24		0.14	[0.11][0.16]	1.89E-27	
FoodInsecurity	0.08	[0.05] $0.11]$	4.97E-09		0.06	[0.04] [0.09]	3.14E-07		0.07	[0.05]	4.26E-08	
LowsSocialsSupport	0.16	[0.07]10.25]	6.41E-04		0.22	[0.13] [0.31]	1.11E-06		0.21	[0.11330.30]	2.02E-05	
Poor Mental Health	0.04	[-0.04]30.12]	0.338		0.03	[-0.04]30.11]	0.382		0.04	[-0.04] [-0.12]	0.290	

For this this to be supported to be supported